Journal
FRONTIERS IN NUTRITION
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnut.2022.886988
Keywords
lycopene; anti-metastasis; adjuvant; sorafenib; MAPK pathway; NOX4
Categories
Funding
- Ministry of Science and Technology of Taiwan [MOST 105-2320-B-040-017-MY3]
Ask authors/readers for more resources
The study demonstrates that the combination of lycopene and sorafenib significantly inhibits lung metastasis of Lewis lung carcinoma cells in mice, reducing the number of metastatic tumors in the lungs. Furthermore, the additive inhibition of mitogen-activated protein kinase (MAPK) pathways contributes to the enhanced anti-metastatic effects of the combined treatment.
Cancer metastasis is the leading cause of death in cancer patients. However, it is unclear whether lycopene can act as an adjuvant to increase the anti-metastatic activity of anticancer drugs. Here, we examined the anti-lung-metastatic effects and the mechanism of lycopene in combination with sorafenib in C57BL/6 mice xenografted with Lewis lung carcinoma (LLC) cells. The mice were divided into five groups: (1) tumor control; (2) lycopene (5 mg/kg); (3) sorafenib (30 mg/kg); (4) lycopene (2 mg/kg) + sorafenib (30 mg/kg); (5) lycopene (5 mg/kg) + sorafenib (30 mg/kg). The results showed that lycopene reduced the number of metastatic tumors in the lungs, which was further suppressed by the combined treatment with sorafenib. The activities of matrix metalloproteinase (MMP)-2 and-9 were further inhibited and TIMP-1 and-2, and NM23-H1, the MMPs negative modulators, were further activated in the combined treatment. Mechanistically, we found that lycopene and sorafenib could additively inhibit the mitogen-activated protein kinase (MAPK) pathways, as shown by the protein phosphorylation of ERK1/2, JNK1/2 and p38 were reduced additively. Overall, the present study demonstrates that lycopene in combination with sorafenib additively inhibits the lung metastasis of tumor, indicating lycopene has potential as an adjuvant for sorafenib in cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available